FGFR3-specific monoclonal antibodies, vofatamab, showed great effectiveness in inhibiting the progression of FGFR3-associated bladder cancer,109 which provides the potential for the usage of FGFR3 antibodies in treating ACH. This evidence concerns the gene FGFR3 and urinary bladder carcinoma.